Corticosteroid treatment in sarcoidosis

• Published in: The European respiratory journal Vol. 28; no. 3; pp. 627 - 636
• Main Authors: Grutters, J. C, van den Bosch, J. M. M
• Format: Journal Article
• Language: English
• Published: Leeds Eur Respiratory Soc 01.09.2006; Maney
• Subjects: Adrenal Cortex Hormones - pharmacology; Adrenal Cortex Hormones - therapeutic use; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Drug Therapy, Combination; Humans; Immune System - drug effects; Immunosuppressive Agents - therapeutic use; Medical sciences; Pharmacology. Drug treatments; Pneumology; Sarcoidosis - diagnosis; Sarcoidosis - drug therapy; Sarcoidosis - immunology; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Corticosteroid; Treatment; Corticosteroids; Sarcoidosis; Systemic disease
• ISSN: 0903-1936; 1399-3003
• DOI: 10.1183/09031936.06.00105805

At present there is no curative treatment for sarcoidosis. Immunosuppressive and/or immunomodulatory drugs can, however, be used for controlling the disease. Corticosteroids remain the mainstay of therapy. They function by suppressing the pro-inflammatory cytokines and chemokines that are involved in cell-mediated immune responses and granuloma formation. Only in a select group of patients is it justifiable to use these drugs, after careful evaluation of the pros and cons. Importantly, disease severity, e.g. threatened organ functions, and not disease activity itself should be the deciding factor in this process. In the case of parenchymal involvement, there is substantial evidence that corticosteroids can improve respiratory symptoms and chest radiography and lung function parameters over 6-24 months. Other generally acknowledged (empirical) criteria for systemic treatment include neurological, cardiac and sight-threatening ocular involvement and hypercalcaemia. Remarkably, despite >50 yrs of use, there is no proof of long-term (survival) benefit from corticosteroid treatment. In addition, there are still no data regarding the optimal dose and duration of corticosteroid or other immunosuppressive therapy. One of the weightiest questions remaining is whether or not these drugs can prevent scarring in patients with a fibrogenic phenotype. As new agents, including infliximab and thalidomide, enter the stage and new diagnostic tools are now available, there is clearly a momentum to design multicentric randomised controlled trials with long enough follow-up (>5 yrs) to answer this pivotal question.